Lin BioScience, Inc.
6696
Rang in aandelen
#3907
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Aandeelprijs
$5.03
Marktkapitalisatie
$4.17B
Verandering (1 dag)
-5.81%
Verandering (1 jaar)
-44.72%
Land
TW
Handel Lin BioScience, Inc. (6696)
Categorie
Healthcare
Koersgeschiedenis voor Lin BioScience, Inc. (6696)
Hoogste slotkoers: $5.40 op 2026-10-01
Laagste slotkoers: $1.30 op 2018-10-01
Laagste slotkoers: $1.30 op 2018-10-01
Koersgeschiedenis van Lin BioScience, Inc. van 2018 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -4.14% |
| 2025 | 202.95% |
| 2024 | 13.59% |
| 2023 | -31.65% |
| 2022 | -22.82% |
| 2021 | 101.12% |
| 2020 | 278.57% |
| 2019 | -21.27% |
| 2018 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.48 | 7.66% |
CH
|
